Leo Pharma has applied for expanded approval for eczema treatment in EU

At the same time as launching tralokinumab in the EU and US, Leo Pharma is also trying to expand the approved patient group for the treatment.

Photo: Leo Pharma/PR

The EU Committee for Medicinal Products for Human Use (CHMP) has convened its monthly meeting, with a Danish treatment on the agenda.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs